The 20 most recent market catalysts affecting $PTCT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Raises Price Target on PTC Therapeutics
Citigroup, a major financial institution, has raised its price target for PTC Therapeutics (PTCT) from $108 to $109 and maintained its 'Buy' rating. This indicates a slightly impro…
Nov 2, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy Rating and Raises Price Target for PTC Therapeutics
Citigroup's decision to maintain a 'Buy' rating and slightly raise the price target for PTC Therapeutics (PTCT) from $108 to $109 signals continued analyst confidence in the compan…
Oct 30, 2026
Corporate Catalyst
Bullish
Impact 65
TD Cowen Maintains PTC Therapeutics at Buy, Raises Price Target to $95
TD Cowen, a prominent investment bank, has maintained its 'Buy' rating on PTC Therapeutics and raised its price target to $95 from $90. This move signals continued confidence in th…
Oct 30, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains PTC Therapeutics at Overweight, Raises Price Target to $112
Wells Fargo maintained its 'Overweight' rating on PTC Therapeutics and raised its price target to $112 from $109. This move signals continued analyst confidence in the company's pr…
Oct 30, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Raises Price Target on PTC Therapeutics to $77
RBC Capital Markets raised its price target for PTC Therapeutics (PTCT) from $75 to $77, following the company's third-quarter 2026 financial results and updated full-year 2026 rev…
Oct 29, 2026
Corporate Catalyst
Bearish
Impact 85
PTC Therapeutics Reports Third-Quarter 2026 Financial Results
PTC Therapeutics announced its third-quarter 2026 financial results, revealing a substantial 69.6% increase in revenue, largely attributed to sales of Sephience. This indicates str…
Oct 29, 2026
Corporate Catalyst
Bullish
Impact 75
PTC Therapeutics Increases Full Year 2026 Financial Guidance
PTC Therapeutics announced an upward revision to its full-year 2026 financial guidance. The company now expects total revenue to be between $1.29 billion and $1.32 billion, and tot…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 55
Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137
Cantor Fitzgerald analyst Kristen Kluska maintained an 'Overweight' rating on PTC Therapeutics and raised the price target from $130 to $137. This action signals continued confiden…
Sep 11, 2026
Corporate Catalyst
Neutral
Impact 75
FDA Approves First Therapy To Target Muscle Loss In Spinal Muscular Atrophy In Patients Aged 2 Years And Older
The FDA's approval of the first therapy to target muscle loss in Spinal Muscular Atrophy (SMA) for patients aged 2 years and older is a significant medical breakthrough. This direc…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122
Barclays analyst Eliana Merle maintained an Overweight rating on PTC Therapeutics and raised the price target from $120 to $122. This action signals continued bullish sentiment fro…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 85
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'
PTC Therapeutics (PTCT) is acquiring the ST-920 Fabry disease program from Sangamo Therapeutics through a competitive bankruptcy auction. This is a significant corporate catalyst f…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109
Wells Fargo analyst Benjamin Burnett maintained an 'Overweight' rating on PTC Therapeutics and raised the price target from $106 to $109. This action signals a continued positive o…
Aug 12, 2026
Corporate Catalyst
Neutral
Impact 92
PTC Therapeutics To Acquire BLA-Stage ST-920 Fabry Disease Program; Terms Include $111M Upfront And Up To $100M In Contingent Milestone Payments Based On Certain Regulatory Approvals
PTC Therapeutics has acquired ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics in a bankruptcy auction. This is a significant strategic move for PT…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $104
Morgan Stanley analyst Jeffrey Hung has maintained an 'Overweight' rating on PTC Therapeutics (PTCT) and raised its price target from $93 to $104. This action signals increased con…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $106
Wells Fargo analyst Benjamin Burnett maintained an 'Overweight' rating on PTC Therapeutics and raised the price target from $93 to $106. This action signals increased confidence fr…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
PTC Therapeutics Raises FY2026 Sales Guidance from $1.080B-$1.180B to $1.180B-$1.280B vs $1.196B Est
PTC Therapeutics announced an upward revision to its fiscal year 2026 sales guidance, moving from a range of $1.080 billion-$1.180 billion to $1.180 billion-$1.280 billion. This ne…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
PTC Therapeutics Q2 EPS $0.92 Beats $0.23 Estimate, Sales $360.519M Beat $298.963M Estimate
This headline is a strong positive catalyst for PTC Therapeutics (PTCT). Beating both EPS and sales estimates by such a significant margin suggests better-than-expected product upt…
Jul 20, 2026
Corporate Catalyst
Bearish
Impact 55
Wells Fargo Maintains Overweight on PTC Therapeutics, Lowers Price Target to $93
Wells Fargo analyst Benjamin Burnett reiterated an 'Overweight' rating on PTC Therapeutics (PTCT), signaling continued confidence in the company's fundamentals and future performan…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 55
Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $130
Cantor Fitzgerald analyst Kristen Kluska maintained an 'Overweight' rating on PTC Therapeutics and raised the price target from $124 to $130. This action signals continued confiden…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.